


COMPLETE LIST OF CLAIMS

Claims 1 – 48 (**Canceled**)


Claim 49 (**New**): A water-soluble tin mesoporphyrin compound comprising a tin mesoporphyrin component complexed with at least one amino acid component, wherein the compound is water-soluble, and wherein said tin mesoporphyrin component has the following formula:



Claim 50 (**New**): The water-soluble tin mesoporphyrin compound of claim 49, wherein the compound is in liquid or solid form.

Claim 51 (New): The water-soluble tin mesoporphyrin compound of claim 49, wherein the amino acid is selected from the group consisting of arginine, glycine, alanine, leucine, serine, lysine, histidine, phenylalanine, tyrosine, and combinations thereof.

Claim 52 (New): A pharmaceutical formulation comprising: at least one pharmaceutically acceptable carrier and a water-soluble tin mesoporphyrin compound, said water-soluble tin mesoporphyrin compound comprising: a tin mesoporphyrin component complexed with at least one amino acid component, wherein the compound is water-soluble, and wherein said tin mesoporphyrin component has the following formula:




Claim 53 (New): The pharmaceutical formulation of claim 52, wherein the water-soluble compound is in liquid or solid form.

Claim 54 (New): The pharmaceutical formulation of claim 52, wherein the amino acid is selected from the group consisting of arginine, glycine, alanine, leucine, serine, lysine, histidine, phenylalanine, tyrosine, and combinations thereof.

Claim 55 (New): The pharmaceutical formulation of claim 52, wherein the formulation contains between about 0.1 and about 50 mg of the tin mesoporphyrin component.

Claim 56 (New): A method of treating a human being with a heme metabolism disorder comprising administering to said human being a pharmaceutically effective amount of a water-soluble tin mesoporphyrin compound comprising a tin mesoporphyrin component complexed with at least one amino acid component, wherein the compound is water-soluble, and wherein said tin mesoporphyrin component has the following formula:



Claim 57 (New): The method of claim 56, wherein the amino acid is selected from the group consisting of arginine, glycine, alanine, leucine, serine, lysine, histidine, phenylalanine, tyrosine, and combinations thereof.

Claim 58 (New): The method of claim 57, wherein the disorder is hyperbilirubinemia.

Claim 59 (New): The method of claim 57, wherein the disorder is psoriasis.

Claim 60 (New): A water-soluble tin mesoporphyrin compound comprising a tin mesoporphyrin component complexed with at least one amino acid component, wherein the

compound is water-soluble, and wherein said tin mesoporphyrin component is tin (IV) mesoporphyrin IX dichloride (or stannsoporfin).

Claim 61 (New): The water-soluble tin mesoporphyrin compound of claim 60, wherein the compound is in liquid or solid form.

Claim 62 (New): The water-soluble tin mesoporphyrin compound of claim 60, wherein the amino acid is selected from the group consisting of arginine, glycine, alanine, leucine, serine, lysine, histidine, phenylalanine, tyrosine, and combinations thereof.

Claim 63 (New): A pharmaceutical formulation comprising: at least one pharmaceutically acceptable carrier and a water-soluble tin mesoporphyrin compound, said water-soluble tin mesoporphyrin compound comprising: a tin mesoporphyrin component complexed with at least one amino acid component, wherein the compound is water-soluble, and wherein said tin mesoporphyrin component is tin (IV) mesoporphyrin IX dichloride (or stannsoporfin).

Claim 64 (New): The pharmaceutical formulation of claim 63, wherein the water-soluble compound is in liquid or solid form.

Claim 65 (New): The pharmaceutical formulation of claim 63, wherein the amino acid is selected from the group consisting of arginine, glycine, alanine, leucine, serine, lysine, histidine, phenylalanine, tyrosine, and combinations thereof.

Claim 66 (New): The pharmaceutical formulation of claim 63, wherein the formulation contains between about 0.1 and about 50 mg of tin (IV) mesoporphyrin IX dichloride (or stannsoporfin).

Claim 67 (New): A method of treating a human being with a heme metabolism disorder comprising administering to said human being a pharmaceutically effective amount of a water-soluble tin mesoporphyrin compound comprising a tin mesoporphyrin component complexed with at least one amino acid component, wherein the compound is water-soluble, and wherein said tin mesoporphyrin component is tin (IV) mesoporphyrin IX dichloride (or stannsoporfin).

Claim 68 (New): The method of claim 67, wherein the amino acid is selected from the group consisting of arginine, glycine, alanine, leucine, serine, lysine, histidine, phenylalanine, tyrosine, and combinations thereof.

Claim 69 (New): The method of claim 68, wherein the disorder is hyperbilirubinemia.

Serial No: 10/713,889
Filed: November 14, 2003

Claim 70 (New): The method of claim 68, wherein the disorder is psoriasis.